SICHUAN GOLDSTONE ASIA PHARMACEUTICAL INC.

Sichuan Goldstone Asia Pharmaceutical Inc.

300434

CNE100001YX5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 30/06/2024 BST			5-day change	1st Jan Change
7.61 ^CNY	+1.47%		-4.52%	-31.19%

06-24	Sichuan Goldstone Asia Pharmaceutical Inc.(XSEC:300434) dropped from S&P Global BMI Index	CI
05-27	Sichuan Goldstone Asia Pharmaceutical Inc. Approves Cash Dividend on A Shares for 2023, Payable on 28 June 2024	CI

Sichuan Goldstone Asia Pharmaceutical Inc.(XSEC:300434) dropped from S&P Global BMI Index

June 23, 2024

Latest news about Sichuan Goldstone Asia Pharmaceutical Inc.

Sichuan Goldstone Asia Pharmaceutical Inc.(XSEC:300434) dropped from S&P Global BMI Index	06-23	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Approves Cash Dividend on A Shares for 2023, Payable on 28 June 2024	05-27	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Proposes Final Cash Dividend for 2023	04-26	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Hangzhou Solipharma Technology Development Co., Ltd. announced that it expects to receive CNY 69.4857 million in funding from Sichuan Goldstone Asia Pharmaceutical Inc., Hangzhou Huolongguo Investment Management Co., Ltd. and another investor	12-27	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Approves Management Appointments	12-25	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/10/23	CI
Sichuan Goldstone Asia Pharmaceutical Inc.(XSEC:300434) added to S&P Global BMI Index	17/09/23	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/04/23	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	24/04/23	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	24/10/22	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	26/08/22	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	25/04/22	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/10/21	CI
Gao Yaping completed the acquisition of 5.1% shares of Sichuan Goldstone Asia Pharmaceutical Inc. from Kuai Yixi and Yang Xiaodong.	15/09/21	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	26/08/21	CI
Gao Yaping signed an equity transfer agreement to acquire 5.1% shares of Sichuan Goldstone Asia Pharmaceutical Inc. from Kuai Yixi and Yang Xiaodong for approximately CNY 170 million.	29/07/21	CI
Sichuan Goldstone Orient New Material Equipment Co., Ltd. Approves Final Cash Dividend for the Year 2020	24/05/21	CI
Sichuan Goldstone Asia Pharmaceutical Inc. signed Equity Acquisition agreement to acquire 65.40% stake in Zhejiang Jiande Zhengfa Pharmaceutical Co.Ltd from group of shareholders for approximately CNY 150 million	19/05/21	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	26/04/21	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21/04/21	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Announces Management Changes	19/11/20	CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2020	28/10/20	CI
Hangzhou Innovative Chinese Medicine Standardization Research Institute Co., Ltd. announced that it expects to receive CNY 6 million in funding from Sichuan Goldstone Asia Pharmaceutical Inc.	27/10/20	CI

Chart Sichuan Goldstone Asia Pharmaceutical Inc.

Duration

Period

Chart Sichuan Goldstone Asia Pharmaceutical Inc.

More charts

Sichuan Goldstone Asia Pharmaceutical Inc., formerly Sichuan Goldstone Orient New Material Equipment Inc, is a China-based company principally engaged in the production and sales of pharmaceutical products, as well as drug agency business. Its main products include health products, cracks and small cracks. The Company is also engaged in the machinery manufacturing business, as well as property leasing and management business. Its machinery products mainly include steel reinforced plastic pipe production line, bead winding steel reinforced pipe production line, production line equipment parts and other equipment. The Company mainly operates its businesses in domestic market.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SICHUAN GOLDSTONE ASIA PHARMACEUTICAL INC.	-31.19%	415M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.70%	43.77B
OTSUKA HOLDINGS CO., LTD.	+30.16%	22.83B
CIPLA LIMITED	+18.68%	14.34B
ZYDUS LIFESCIENCES LIMITED	+54.86%	12.96B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.72%	6.41B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.65%	5.69B
GEDEON RICHTER	+9.49%	4.75B

Generic Pharmaceuticals